Inclusion Criteria:

          1. Subject is willing and able to provide written informed consent for the study prior to
             the performance of any study-specific procedures

          2. Subject is a male or female subject ≥18 years of age at the time of consent

          3. Subject must have an ECOG PS ≤ 1

          4. Subject must have histologically or cytologically confirmed advanced or metastatic
             solid tumor

          5. There is no available standard systemic treatment for the subject's tumor histology
             and/or molecular biomarker profile

          6. Subject must have radiographically measurable or evaluable disease

          7. Subject must have recovered from the reversible effects of prior anti-neoplastic
             therapy, except for alopecia and ≤ grade 2 neuropathy.

          8. Subject has adequate end organ function

          9. Subject is willing to comply with all protocol-required visits, assessments, and
             procedures

         10. Male and female subjects of child-bearing potential are willing to use medically
             acceptable methods of birth control from the screening visit through 30 days after the
             last dose of study medication

        Exclusion Criteria:

          1. Subjects with documented history of tumor mutations that may not be amenable to
             treatment with RLY-1971, including

               1. KRAS mutations: G12D, G12V, G13X, and Q61X

               2. BRAF V600E mutation

               3. MEK mutations

          2. Subjects with prior antineoplastic therapy within 3 weeks of Study Day 1, or 5
             half-lives, whichever is shorter

          3. Subjects with prior palliative radiotherapy within 1 week of Study Day 1

          4. Subjects who have had major surgery or trauma, or incomplete recovery from surgery or
             trauma, within 4 weeks of Study Day 1

          5. Subjects with known central nervous system (CNS) primary tumor, uncontrolled CNS
             metastases, or carcinomatous meningitis. Subjects with stable or asymptomatic brain
             metastases are eligible to participate

          6. Subjects with a history or evidence of ophthalmic disease

          7. Subjects with a history or evidence of significant cardiac dysfunction

          8. Subjects with a history or evidence of significant gastrointestinal disease

          9. Subjects with other serious concurrent medical conditions